Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
Kim DW, Lee DH, Han JY, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim JS, Min YJ, Cho JY, An HJ, Kim HG, Lee KH, Kim BS, Jang IJ, Yoon S, Han O, Noh YS, Hong KY, Park K.
Kim DW, et al. Among authors: cho ek, cho jy, cho bc.
Lung Cancer. 2019 Sep;135:66-72. doi: 10.1016/j.lungcan.2019.07.007. Epub 2019 Jul 9.
Lung Cancer. 2019.
PMID: 31447004
Clinical Trial.